A 3D Monte Carlo Method for Estimation of Patient-specific Internal Organs Absorbed Dose for (99m)Tc-hynic-Tyr(3)-octreotide Imaging

Overview

Journal World J Nucl Med

Publisher Thieme

Specialty Nuclear Medicine

Date 2016 May 3

PMID 27134562

Citations 7

Authors

Mehdi Momennezhad

Shahrokh Nasseri

Seyed Rasoul Zakavi

Ali Asghar Parach

Mahdi Ghorbani

Ruhollah Ghahraman Asl

Affiliations

Soon will be listed here.

Abstract

Single-photon emission computed tomography (SPECT)-based tracers are easily available and more widely used than positron emission tomography (PET)-based tracers, and SPECT imaging still remains the most prevalent nuclear medicine imaging modality worldwide. The aim of this study is to implement an image-based Monte Carlo method for patient-specific three-dimensional (3D) absorbed dose calculation in patients after injection of (99m)Tc-hydrazinonicotinamide (hynic)-Tyr(3)-octreotide as a SPECT radiotracer. (99m)Tc patient-speciﬁc S values and the absorbed doses were calculated with GATE code for each source-target organ pair in four patients who were imaged for suspected neuroendocrine tumors. Each patient underwent multiple whole-body planar scans as well as SPECT imaging over a period of 1-24 h after intravenous injection of (99m)hynic-Tyr(3)-octreotide. The patient-specific S values calculated by GATE Monte Carlo code and the corresponding S values obtained by MIRDOSE program differed within 4.3% on an average for self-irradiation, and differed within 69.6% on an average for cross-irradiation. However, the agreement between total organ doses calculated by GATE code and MIRDOSE program for all patients was reasonably well (percentage difference was about 4.6% on an average). Normal and tumor absorbed doses calculated with GATE were slightly higher than those calculated with MIRDOSE program. The average ratio of GATE absorbed doses to MIRDOSE was 1.07 ± 0.11 (ranging from 0.94 to 1.36). According to the results, it is proposed that when cross-organ irradiation is dominant, a comprehensive approach such as GATE Monte Carlo dosimetry be used since it provides more reliable dosimetric results.

Citing Articles

Monte Carlo methods for medical imaging research.

Lee H Biomed Eng Lett. 2024; 14(6):1195-1205.

PMID: 39465109 PMC: 11502642. DOI: 10.1007/s13534-024-00423-x.

Prediction of Absorbed Dose to Normal Organs with Endocrine Tumors for I-131 by use of TC Single Photon Emission Computed Tomography/Computed Tomography and Geant4 Application for Tomographic Emission Simulation.

Asl R, Sabbaghi R, Ahangari H, Hejazi P, Foroutan M Indian J Nucl Med. 2021; 36(3):273-281.

PMID: 34658551 PMC: 8481846. DOI: 10.4103/ijnm.ijnm_6_21.

Quantification of internal dosimetry in PET patients: individualized Monte Carlo vs generic phantom-based calculations.

Neira S, Guiu-Souto J, Diaz-Botana P, Pais P, Fernandez C, Pubul V Med Phys. 2020; 47(9):4574-4588.

PMID: 32569389 PMC: 7586975. DOI: 10.1002/mp.14344.

Estimating the Absorbed Dose of Organs in Pediatric Imaging of Tc-DTPATc-DTPA Radiopharmaceutical using MIRDOSE Software.

K E, R A, F K, N A, A B, Gh A J Biomed Phys Eng. 2019; 9(3):285-294.

PMID: 31341874 PMC: 6613160. DOI: 10.31661/jbpe.v0i0.984.

Deformable torso phantoms of Chinese adults for personalized anatomy modelling.

Wang H, Sun X, Wu T, Li C, Chen Z, Liao M J Anat. 2018; 233(1):121-134.

PMID: 29663370 PMC: 5987821. DOI: 10.1111/joa.12815.

References

Decristoforo C, Mather S, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R . 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med. 2000; 27(9):1318-25. DOI: 10.1007/s002590000289. View

Shinto A, Kamaleshwaran K, Mallia M, Korde A, Samuel G, Banerjee S . Utility of (99m)Tc-Hynic-TOC in 131I Whole-Body Scan Negative Thyroid Cancer Patients with Elevated Serum Thyroglobulin Levels. World J Nucl Med. 2015; 14(2):101-8. PMC: 4455165. DOI: 10.4103/1450-1147.154229. View

Grimes J, Celler A . Comparison of internal dose estimates obtained using organ-level, voxel S value, and Monte Carlo techniques. Med Phys. 2014; 41(9):092501. DOI: 10.1118/1.4892606. View

Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C . Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide. Eur J Nucl Med Mol Imaging. 2012; 40(3):364-72. DOI: 10.1007/s00259-012-2286-6. View

Loke K, Padhy A, Ng D, Goh A, Divgi C . Dosimetric considerations in radioimmunotherapy and systemic radionuclide therapies: a review. World J Nucl Med. 2011; 10(2):122-38. PMC: 3227338. DOI: 10.4103/1450-1147.89780. View

Ichihara T, Ogawa K, Motomura N, Kubo A, Hashimoto S . Compton scatter compensation using the triple-energy window method for single- and dual-isotope SPECT. J Nucl Med. 1993; 34(12):2216-21. View

Dewaraja Y, Wilderman S, Ljungberg M, Koral K, Zasadny K, Kaminiski M . Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation. J Nucl Med. 2005; 46(5):840-9. PMC: 2804106. View

Marcatili S, Villoing D, Mauxion T, McParland B, Bardies M . Model-based versus specific dosimetry in diagnostic context: comparison of three dosimetric approaches. Med Phys. 2015; 42(3):1288-96. DOI: 10.1118/1.4907957. View

Kost S, Dewaraja Y, Abramson R, Stabin M . VIDA: a voxel-based dosimetry method for targeted radionuclide therapy using Geant4. Cancer Biother Radiopharm. 2015; 30(1):16-26. PMC: 4322792. DOI: 10.1089/cbr.2014.1713. View

10.

Papadimitroulas P, Loudos G, Nikiforidis G, Kagadis G . A dose point kernel database using GATE Monte Carlo simulation toolkit for nuclear medicine applications: comparison with other Monte Carlo codes. Med Phys. 2012; 39(8):5238-47. DOI: 10.1118/1.4737096. View

11.

Divoli A, Chiavassa S, Ferrer L, Barbet J, Flux G, Bardies M . Effect of patient morphology on dosimetric calculations for internal irradiation as assessed by comparisons of Monte Carlo versus conventional methodologies. J Nucl Med. 2009; 50(2):316-23. DOI: 10.2967/jnumed.108.056705. View

12.

Stabin M, Sparks R, Crowe E . OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005; 46(6):1023-7. View

13.

Bolch W, Eckerman K, Sgouros G, Thomas S . MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature. J Nucl Med. 2009; 50(3):477-84. DOI: 10.2967/jnumed.108.056036. View

14.

Zeintl J, Vija A, Yahil A, Hornegger J, Kuwert T . Quantitative accuracy of clinical 99mTc SPECT/CT using ordered-subset expectation maximization with 3-dimensional resolution recovery, attenuation, and scatter correction. J Nucl Med. 2010; 51(6):921-8. DOI: 10.2967/jnumed.109.071571. View

15.

ODonoghue J . Implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med. 1999; 40(8):1337-41. View

16.

Eckerman K, Endo A . ICRP Publication 107. Nuclear decay data for dosimetric calculations. Ann ICRP. 2009; 38(3):7-96. DOI: 10.1016/j.icrp.2008.10.004. View

17.

Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Watfah Rychlinski C, Mather S . An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med. 2003; 44(5):708-16. View

18.

Parach A, Rajabi H, Askari M . Paired organs-should they be treated jointly or separately in internal dosimetry?. Med Phys. 2011; 38(10):5509-21. DOI: 10.1118/1.3637493. View

19.

. Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53). Ann ICRP. 2000; 28(3):1-126. DOI: 10.1016/s0146-6453(99)00006-8. View

20.

Lyra M, Lagopati N, Charalambatou P, Vamvakas I . Patient-specific dosimetry in radionuclide therapy. Radiat Prot Dosimetry. 2011; 147(1-2):258-63. DOI: 10.1093/rpd/ncr329. View